OraSure Technologies (OSUR) vs STAAR Surgical (STAA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OraSure Technologies (OSUR) has outperformed STAAR Surgical (STAA) over the past year, gaining 18.0% versus a loss of 16.3%. Over five years, OSUR leads with a -64.5% price change compared with -80.5% for STAA. STAAR Surgical is the larger company by market cap ($1.12 billion vs $257.3 million), about 4.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OSUR | STAA |
|---|---|---|
| Share price | $3.73 | $22.36 |
| Market cap | $257.25M | $1.12B |
| 1-day change | -1.06% | +0.95% |
| YTD return | +54.13% | -3.16% |
| 1-year return | +18.04% | -16.32% |
| 5-year return | -64.51% | -80.54% |
| P/E ratio (TTM) | — | 279.50 |
| Forward P/E | — | 20.12 |
| EPS (TTM) | $-0.69 | $0.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.58 | $35.87 |
| 52-week low | $2.08 | $15.59 |
| Distance from 52-week high | -18.56% | -37.66% |
| Analyst consensus | none | buy |
| Avg. price target upside | +7.24% | +25.22% |
| Average volume | 480.98K | 1.00M |
| Shares outstanding | 68.97M | 50.14M |
| Employees | 500 | 921 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STAAR Surgical is about 4.4 times larger than OraSure Technologies by market value ($1.12B vs $257.25M).
- OSUR has outperformed STAA by 34.4 percentage points over the past year.
About OraSure Technologies
OSUR stock →OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Health Care · Medical/Dental Instruments · 500 employees
About STAAR Surgical
STAA stock →STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Health Care · Ophthalmic Goods · 921 employees
OSUR vs STAA FAQ
Which is bigger, OraSure Technologies or STAAR Surgical?
STAAR Surgical (STAA) is larger, with a market capitalization of $1.12B compared with $257.25M for OraSure Technologies (OSUR).
Which stock has performed better over the past year, OSUR or STAA?
OSUR returned +18.04% over the past 12 months, compared with -16.32% for STAA (price return, excluding dividends). Past performance does not predict future results.
Are OraSure Technologies and STAAR Surgical in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for OraSure Technologies and Ophthalmic Goods for STAAR Surgical.